INVESTIGATION OF TREPONEMA PALLIDUM ANTIBODY TITER BY USING TPHA AND RPR IN NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY

Văn An Nguyễn1, Văn Hưng Lê2,3, Hữu Doanh Lê2,3, Quỳnh Hoa Phạm3, Thị Hà Vinh Nguyễn2,3, Huy Lượng Vũ2,3, Hạ Long Hải Lê2,3,, Hoàng Việt Nguyễn2, Huy Hoàng Lê4, Thùy Trang Nguyễn5
1 103 Military Hospital
2 HMU
3 National Hospital of Dermatology and Venereology
4 Central Institute of Hygiene and Epidemiology
5 Vietnam National Children's Hospital.

Main Article Content

Abstract

Syphilis is one of the most common sexually transmitted infections (STIs) in Vietnam and worldwide. Untreated syphilis can cause damage to the nervous system, cardiovascular system, liver, bone, and other complications. Method: This cross-sectional study aimed to measure the levels of syphilis antibody titer using Treponema pallidum hemagglutination antibody (TPHA) and rapid plasma reagin (RPR) simultaneously. Blood specimens were collected from 206 males and 120 females who attended the National Hospital of Dermatology and Venereology from October 2021 to December 2021. Results: Of 326 blood specimens, 274 (84.0%) and 165 (50.6%) were positive for TPHA and RPR, respectively. The specimens with a high level of antibody titer in TPHA (≥10240) and RPR (≥32) testings were 59 (18.1%) and 48 (14.7%), respectively. The prevalence of high titer was lower in females than males for both TPHA and RPR testings. There was no significant difference in high titer between attendees with and without STI diagnostics. Conclusions: This study showed the high seroprevalence of syphilis among patients who attended the National Hospital of Dermatology and Venereology. Both qualitative and quantitative TPHA and RPR should be recommended for syphilis screening and diagnosing.

Article Details

References

1. Centers for Disease Control and Prevention (CDC) (2021), FDA Alert: Possible False RPR Reactivity with Syphilis Test. 18 Feb 2023]; Available from: https://www.cdc.gov/ std/dstdp/dcl/FDA-alert-12-20-2021.pdf.
2. Centers for Disease Control and Prevention (CDC) (2022), Syphilis Statistics. [Accessed: 21 Feb 2023; Available from: https://www.cdc.gov/std/syphilis/stats.htm.
3. Drago, F., et al. (2015), Screening, treatment, and follow-up of syphilis patients: Issues, concerns and efforts to improve current paradigms. Indian J Sex Transm Dis AIDS. 36(1): p. 112-4.
4. Peeling, R.W., et al. (2017), Syphilis. Nat Rev Dis Primers. 3: p. 17073.
5. Satyaputra, F., et al. (2021), The Laboratory Diagnosis of Syphilis. J Clin Microbiol. 59(10): p. e0010021.
6. Wiwanitkit, V. (2009), A cost-utility analysis of Treponema pallidum haemagglutination (TPHA) testing for syphilis screening of blood donors: is the TPHA test useful for syphilis screening in a blood centre? Blood Transfus. 7(1): p. 65-6.
7. Wong, T., et al. (2004), Gender Differences in Bacterial STIs in Canada. BMC Womens Health. 4 Suppl 1(Suppl 1): p. S26.
8. World Health Organization (WHO) (2022), Sexually transmitted infections (STIs). [Accessed: 2023 16 Feb]; Available from: https:// www.who.int/news-room/fact-sheets/detail/ sexually-transmitted-infections-(stis).